AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28503827 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-mounted keratoscopy
Number of subjects: 22
Study 28503827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held keratoscopy
Number of subjects: 22
Study 27352493 — intervention group
Group type: EXPERIMENTAL
Intervention: 'jin' theory acupuncture
Number of subjects: 95
Study 27352493 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 95
Study 27352493 — intervention group
Group type: COMPARATOR
Intervention: Medication (betahistine mesylate)
Number of subjects: 95
Study 24561488 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily voglibose
Number of subjects: 151
Study 24561488 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily voglibose
Number of subjects: 151
Study 24561488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 22570073 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (AA group)
Number of subjects: 66
Study 22570073 — intervention group
Group type: COMPARATOR
Intervention: Classic approach (CA group)
Number of subjects: 66
Study 20647773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg/dose, once a week for six weeks) with chemoradiation
Number of subjects: 92
Study 20647773 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 92
Study 17548746 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 817
Study 17548746 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 817
Study 17548746 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 817
Study 17548746 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 817
Study 17548746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 817
Study 15770976 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐SPECT in patients with GEs
Number of subjects: 22
Study 15770976 — intervention group
Group type: COMPARATOR
Intervention: ECHO
Number of subjects: 22
Study 11926695 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ibuprofen 5% gel (Ibugel)
Number of subjects: 81
Study 11926695 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 81
Study 9869212 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery (R+S)
Number of subjects: 370
Study 9869212 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 370
Study 7543038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg morphine
Number of subjects: 29
Study 7543038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg nalbuphine
Number of subjects: 29
Study 7543038 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study 2198909 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 182
Study 2198909 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaveretum-hyoscine
Number of subjects: 182
Study 2198909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 328192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (1.2 g.kg‐1)
Number of subjects: 12
Study 328192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose (1.2 g.kg‐1)
Number of subjects: 12
Study 328192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30689608 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled ripcord removal
Number of subjects: 81
Study 28589334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed bearing implant
Number of subjects: 40
Study 28589334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing implant
Number of subjects: 40
Study 25741971 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvanted PCV15
Number of subjects: 90
Study 25741971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted PCV15
Number of subjects: 90
Study 25741971 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 90
Study 25741971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of PCV15
Number of subjects: 90
Study 23501476 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to steel plant (0.9km)
Number of subjects: 61
Study 23501476 — intervention group
Group type: COMPARATOR
Intervention: College site (4.5km)
Number of subjects: 61
Study 21458143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 98
Study 21458143 — intervention group
Group type: COMPARATOR
Intervention: Free-hand injection without ultrasound guidance
Number of subjects: 98
Study 19266265 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethyleneoxide (PEO) based heparin bonded extracorporeal circuits (ECC) + Continuous Leukocyte filtration
Number of subjects: 40
Study 19266265 — intervention group
Group type: EXPERIMENTAL
Intervention: uncoated ECC + leukofiltration
Number of subjects: 40
Study 19266265 — intervention group
Group type: EXPERIMENTAL
Intervention: PEO based heparin bonded ECC without leukofiltration
Number of subjects: 40
Study 19266265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 17484646 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy
Number of subjects: 712
Study 17484646 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 712
Study 15329029 — intervention group
Group type: COMPARATOR
Intervention: Antibacterials
Number of subjects: 58
Study 15329029 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (antibacterials only if failed to improve after 7 days)
Number of subjects: 58
Study 15329029 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment (all patients initially treated with antibacterials)
Number of subjects: 58
Study 15329029 — intervention group
Group type: COMPARATOR
Intervention: Radiology-guided treatment
Number of subjects: 58
Study 15329029 — intervention group
Group type: COMPARATOR
Intervention: Treatment based on specific clinical criteria
Number of subjects: 58
Study 10649155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol plus 30 microg norgestimate
Number of subjects: 236
Study 10649155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol plus 90 microg norgestimate
Number of subjects: 236
Study 10649155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol plus 180 microg norgestimate
Number of subjects: 236
Study 10649155 — intervention group
Group type: COMPARATOR
Intervention: 1 mg estradiol daily
Number of subjects: 236
Study 9276354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy plus BCNU for AAF/OL patients
Number of subjects: 133
Study 9276354 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy plus BCNU for AAF patients
Number of subjects: 133
Study 8338086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 2 g daily
Number of subjects: 374
Study 8338086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 4 g daily
Number of subjects: 374
Study 8338086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 3566125 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory random noise preoperatively
Number of subjects: 0
Study 3566125 — intervention group
Group type: COMPARATOR
Intervention: No auditory random noise
Number of subjects: 0
Study 31479004 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (amEX)
Number of subjects: 40
Study 31479004 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (pmEX)
Number of subjects: 40
Study 29488628 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal mindfulness training (MMT)
Number of subjects: 0
Study 29488628 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 28660498 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 2.8 mg
Number of subjects: 80
Study 28660498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28660498 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 80
Study 26591622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) mouthwash
Number of subjects: 120
Study 26591622 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils (EO) mouthwash
Number of subjects: 120
Study 26591622 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free, alcohol-free non-antibacterial mouthwash (NC)
Number of subjects: 120
Study 22517190 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes
Number of subjects: 56
Study 22517190 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (42 mg nicotine patches)
Number of subjects: 56
Study 22517190 — intervention group
Group type: COMPARATOR
Intervention: No cigarettes (control condition)
Number of subjects: 56
Study 22517190 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 56
Study 21512399 — intervention group
Group type: EXPERIMENTAL
Intervention: CR2 (0.15 g·kg creatine during 2 d wk of RT)
Number of subjects: 38
Study 21512399 — intervention group
Group type: EXPERIMENTAL
Intervention: CR3 (0.10 g·kg creatine during 3 d wk of RT)
Number of subjects: 38
Study 21512399 — intervention group
Group type: COMPARATOR
Intervention: PLA2 (placebo during 2 d wk of RT)
Number of subjects: 38
Study 21512399 — intervention group
Group type: COMPARATOR
Intervention: PLA3 (placebo during 3 d wk of RT)
Number of subjects: 38
Study 21512399 — intervention group
Group type: EXPERIMENTAL
Intervention: Men on creatine
Number of subjects: 38
Study 21512399 — intervention group
Group type: EXPERIMENTAL
Intervention: Women on creatine
Number of subjects: 38
Study 18283177 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual computerized presentations
Number of subjects: 101
Study 18283177 — intervention group
Group type: COMPARATOR
Intervention: Written handouts
Number of subjects: 101
Study 16493126 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness, Academics & You intervention
Number of subjects: 1013
Study 16493126 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 1013
Study 12964450 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback assisted relaxation therapy (BFRT)
Number of subjects: 22
Study 12964450 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 22
Study 10329103 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 544
Study 10329103 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 544
Study 8712747 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 52
Study 8712747 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 52
Study 8712747 — intervention group
Group type: COMPARATOR
Intervention: Control (no antifungal agent)
Number of subjects: 52
Study 1681560 — intervention group
Group type: EXPERIMENTAL
Intervention: BW234U (two different dosage ranges)
Number of subjects: 0
Study 1681560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 1681560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7036288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy (DTIC 80 mg/m2 + 8 days prior to surgery)
Number of subjects: 469
Study 7036288 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (vinblastine 6 mg/m2, thiotepa 6 mg/m2, rufocromycine 60 microgram/m2, methotrexate 15 mg/m2 on day 1, procarbazine 30 mg/m2 for 7 days)
Number of subjects: 469
Study 7036288 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (chemotherapy identical to above + DTIC 300 mg/m2 for each course + BCG every 4 weeks + C. parvum every week)
Number of subjects: 469
Study 7036288 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 469
Study 31808709 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label chamomile extract 1500 mg daily for 8 weeks
Number of subjects: 179
Study 31801593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle therapy (group A1)
Number of subjects: 160
Study 31801593 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (group A2)
Number of subjects: 160
Study 31801593 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment (group B)
Number of subjects: 160
Study 27989514 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone
Number of subjects: 54
Study 27989514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26564598 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy
Number of subjects: 377
Study 26564598 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib combined with statins
Number of subjects: 377
Study 26564598 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy (rosuvastatin and simvastatin)
Number of subjects: 377
Study 26564598 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy and evacetrapib combined with statins
Number of subjects: 377
Study 23844234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vashe soak
Number of subjects: 47
Study 23844234 — intervention group
Group type: COMPARATOR
Intervention: Soap and water wash
Number of subjects: 47
Study 23844234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vashe wipes
Number of subjects: 47
Study 23844234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined approach (soap and water wash followed by Vashe soak)
Number of subjects: 47
Study 23844234 — intervention group
Group type: COMPARATOR
Intervention: Soap and water bed baths
Number of subjects: 47
Study 23844234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vashe bed baths
Number of subjects: 47
Study 21742095 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 15603
Study 21742095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 15603
Study 19212169 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrojejunostomy
Number of subjects: 75
Study 19212169 — intervention group
Group type: COMPARATOR
Intervention: Billroth II reconstruction
Number of subjects: 75
Study 16317063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 10
Study 16317063 — intervention group
Group type: COMPARATOR
Intervention: Regular + NPH insulin (R+N)
Number of subjects: 10
Study 15623591 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg daily
Number of subjects: 67
Study 15623591 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg daily
Number of subjects: 67
Study 15623591 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg on alternate days
Number of subjects: 67
Study 15623591 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both thalidomide arms)
Number of subjects: 67
Study 12194618 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent practice of sitting balance as an addition to standard physiotherapy treatment based on the Bobath Approach for four weeks.
Number of subjects: 28
Study 12194618 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy treatment based on the Bobath Approach (control group).
Number of subjects: 28
Study 11189402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 116
Study 7598286 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge Sprotte needle
Number of subjects: 234
Study 7598286 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge Sprotte needle
Number of subjects: 234
Study 7598286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 234
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Clindamycin (600 mg)
Number of subjects: 20
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) + Clindamycin (600 mg)
Number of subjects: 20
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) + Clindamycin (600 mg)
Number of subjects: 20
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Metronidazole (500 mg)
Number of subjects: 20
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) + Metronidazole (500 mg)
Number of subjects: 20
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg) + Metronidazole (400 mg)
Number of subjects: 20
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) + Metronidazole (400 mg)
Number of subjects: 20
Study 2088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) + Ornidazole (500 mg)
Number of subjects: 20
Study 520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3600 mg/d)
Number of subjects: 40
Study 520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/d)
Number of subjects: 40
Study 520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/d)
Number of subjects: 40
Study 520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg/d)
Number of subjects: 40
Study 520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/d)
Number of subjects: 40
Study 520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1600 mg/d)
Number of subjects: 40
Study 520100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg/d)
Number of subjects: 40
Study 520100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6356538 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HR (isoniazid and rifampicin for 6 months)
Number of subjects: 851
Study 6356538 — intervention group
Group type: COMPARATOR
Intervention: 4H (isoniazid alone for 6 months)
Number of subjects: 851
Study 6356538 — intervention group
Group type: COMPARATOR
Intervention: 6H (isoniazid alone for 8 months)
Number of subjects: 851
Study 6356538 — intervention group
Group type: COMPARATOR
Intervention: 4HZ (isoniazid and pyrazinamide for 6 months)
Number of subjects: 851
Study 6356538 — intervention group
Group type: COMPARATOR
Intervention: 4H and 6H (isoniazid alone for 6 and 8 months)
Number of subjects: 851
Study 6356538 — intervention group
Group type: EXPERIMENTAL
Intervention: 4H or 6H (isoniazid alone for 6 and 8 months)
Number of subjects: 851
Study 6356538 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 851
Study 31797716 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroSAFE technique
Number of subjects: 407
Study 31797716 — intervention group
Group type: COMPARATOR
Intervention: Non-NeuroSAFE technique
Number of subjects: 407
Study 30016316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis-dependent ACT subsidies with free diagnostic testing
Number of subjects: 32404
Study 30016316 — intervention group
Group type: COMPARATOR
Intervention: Standard package of health education, prevention, and referral services
Number of subjects: 32404
Study 26879183 — intervention group
Group type: EXPERIMENTAL
Intervention: N-back training for healthy subjects
Number of subjects: 35
Study 26879183 — intervention group
Group type: EXPERIMENTAL
Intervention: N-back training for ABI patients
Number of subjects: 35
Study 26879183 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 24285618 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management plus usual care
Number of subjects: 0
Study 24285618 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 22154397 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E, n = 10)
Number of subjects: 32
Study 22154397 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training (ER, n = 10)
Number of subjects: 32
Study 22154397 — intervention group
Group type: COMPARATOR
Intervention: Control (C, n = 12)
Number of subjects: 32
Study 20885293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (0.22 mg/kg)
Number of subjects: 99
Study 20885293 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (34 μg/kg)
Number of subjects: 99
Study 20885293 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 99
Study 17508624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Pulsar (PUL)
Number of subjects: 0
Study 17508624 — intervention group
Group type: COMPARATOR
Intervention: Colgate 360 (COL)
Number of subjects: 0
Study 17508624 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Advantage Plus (AP)
Number of subjects: 0
Study 17508624 — intervention group
Group type: COMPARATOR
Intervention: Oral-B CrossAction (CA)
Number of subjects: 0
Study 17508624 — intervention group
Group type: COMPARATOR
Intervention: Oral-B CrossAction Power (CAP)
Number of subjects: 0
Study 17508624 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush Pro (SBP)
Number of subjects: 0
Study 16236039 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 8
Study 16236039 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study 12022585 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 0
Study 12022585 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10077031 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) 0.1 mmol/kg
Number of subjects: 163
Study 10077031 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) 0.3 mmol/kg
Number of subjects: 163
Study 10077031 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) 0.5 mmol/kg
Number of subjects: 163
Study 10077031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 7548979 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 35
Study 7548979 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 35
Study 2209383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 172